Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential expression analysis of intra- and peritumoral immune-related gene in murine hepatocellular carcinoma

ABSTRACT: As immunotherapy plays an increasingly important role in the treatment of hepatocellular carcinoma, the immune infiltration heterogeneity of the tumor provides an important reference for immunotherapy decisions. In this study, a mouse hepatocellular carcinoma model was established, and the intra-tumor and peritumor tissues were sampled and analyzed by RNA sequencing, respectively, to explore the heterogeneity of immune-related gene expression in intra- and peritumor regions.

ORGANISM(S): Mus musculus

PROVIDER: GSE215098 | GEO | 2022/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Differential expression analysis of intra- and peritumoral immune-related gene in murine hepatocellular carcinoma

Project description:Differential expression analysis of intra- and peritumoral immune-related gene in murine hepatocellular carcinoma

| PRJNA888414 | ENA

Spatial tissue proteomics quantifies inter- and intra-tumor heterogeneity in hepatocellular carcinoma

Project description:The inter-patient variability of tumor proteomes has been investigated on a large scale but many tumors display also intra-tumoral heterogeneity (ITH) regarding morphological and genetic features. To what extent the local proteome of tumors intrinsically differs remains largely unknown. Here, we used hepatocellular carcinoma (HCC) as a model system, to quantify both inter- and intra-tumor heterogeneity across human patient specimens with spatial resolution. We first defined proteomic features that robustly distinguish neoplastic from the directly adjacent non-neoplastic tissue by integrating proteomic data from human patient samples and genetically defined mouse models with available gene expression data. We then demonstrated the existence of intra-tumoral variations in protein abundance that re-occur across different patient samples, and affect clinically relevant proteins, even in the absence of obvious morphological differences or genetic alterations. Our work demonstrates the suitability and the benefits of using mass spectrometry based proteomics to analyze diagnostic tumor specimens with spatial resolution

2018-01-24 | PXD007052 | Pride

Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma

Project description:Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma

| PRJNA385729 | ENA

Human normal and peritumor liver tissues LC-MSMS

Project description:The tumor microenvironment (TME) plays an important role in tumorigenesis1. The TME is usually studied in tumor tissue and in relation to tumor progression2,3, which can limit understanding of how the TME is involved in processes associated with initial tumorigenesis as well as tumor recurrence and metastasis after surgery. To describe the underlying mechanisms of human hepatocellular carcinoma (HCC) occurrence and progression, we propose a new concept, the peritumor microenvironment (PME). We collected normal (all biochemical indicators of liver function, imaging examination and histopathology examination were normal) and peritumor (The liver tissues adjacent to the tumor were approximately 2 cm away from the tumor and were taken from patients with HCC who did not receive tumor radiotherapy, tumor chemotherapy or targeted drug therapy before surgery) to perform a proteomic characterization of the PME in peritumor liver tissues.

2022-02-22 | PXD023118 | Pride

Intra- and inter-tumoral heterogeneity of liver metastases in a patient with uveal melanoma

Project description:Tumour heterogeneity has been the main obstacle to the clinical efficacy of targeted and immunotherapy in cancer. An accurate understanding and recognition of tumour heterogeneity is critical in the clinical management of cancer patients. Here, we utilised single-cell RNA sequencing (scRNA-seq) to uncover the intra- and inter-tumoural heterogeneity of liver metastases from a patient with metastatic uveal melanoma.

2021-09-12 | GSE176029 | GEO

MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma

Project description:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in the world. Mitochondrial fission regulator 2 (MTFR2) is involved in the development of various cancers. However, the roles of MTFR2 in HCC remain unknown. In this study, we conducted a comprehensive analysis of MTFR2 in HCC, which was generated from integrative MTFR2 analyses of eight HCC cell lines, and three datasets (public dataset, real-world dataset, immunotherapy dataset) derived from bulk HCC tissues, survival and immunotherapy data. We demonstrated that the expression level of MTFR2 is up-regulated in HCC, leading to poor prognosis. MTFR2 is positively correlated with the level of immune cell infiltration, multiple immune checkpoints and immunotherapy response prediction pathways, and act important role in cancer-immunity cycle. In conclusion, our work indicates that MTFR2 can shape a barrier of immune microenvironment and result in poor prognosis in hepatocellular carcinoma, but the immune barrier may be broken by immunotherapy.

2022-09-01 | GSE212529 | GEO

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

Project description:This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal carcinoma (CRC) and other solid tumors, including primary hepatocellular carcinoma (HCC). A third arm will study the intra-tumoral injection of Ad-p53 combined with nivolumab infusions in recurrent head and neck squamous cell cancer (HNSCC). This safety study has a standard 3+3 design for arms A and B; .HNSCC will be placed in a single dosing cohort. The Maximum Tolerated Dose (MTD) will be determined as well for intra-arterial infusions, and the entire study will determine the general efficacy using RECIST 1.1 and Immune-Related Response Criteria. Safety will be followed using the CTCAE listings for adverse events.

| 2220501 | ecrin-mdr-crc

Multi-omics identifies the link between intratumor steatosis and exhausted tumor immune microenvironment in hepatocellular carcinoma

Project description:Immunotherapy becomes standard-of-care treatment of hepatocellular carcinoma (HCC) but still limited number of patients benefit from immunotherapy due to the high heterogeneity of tumor immune-microenvironment (TIME) of HCC patients. Therefore, it is important to stratify patients who benefit from immunotherapy by analyzing the molecular and immunological diversity of HCC. Since non-viral HCC is rapidly increasing all over the world, in this study, we focused on non-viral HCC and aimed to identify immunotherapy-susceptible patients through multi-omics. Global RNA sequencing of surgically-resected tumor tissues in 113 non-viral HCC patients was performed. Unsupervised hierarchical clustering classified non-viral HCCs into 3 molecular classes associated with patient prognosis and corresponding driver gene abnormality. We further identified the immune-enriched but -exhausted subclass with intratumor steatosis in non-viral HCCs, characterized by T-cell exhaustion, infiltration of M2 macrophage and cancer-associated fibroblast (CAF), high PD-L1 expression, and TGF-β signaling activation..

2022-05-22 | GSE190967 | GEO

Intra-tumor heterogeneity and clonal evolution of papillary renal cell carcinoma

Project description:Intra-tumor heterogeneity and clonal evolution of papillary renal cell carcinoma

| PRJNA449794 | ENA

Intra-tumor heterogeneity and clonal evolution of papillary renal cell carcinoma

Project description:Intra-tumor heterogeneity and clonal evolution of papillary renal cell carcinoma

| PRJNA449796 | ENA